We are live on ! Find out more
RCUS icon

Arcus Biosciences
RCUS

181 hedge funds and large institutions have $1.11B invested in Arcus Biosciences in 2023 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 59 increasing their positions, 65 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more call options, than puts

Call options by funds: $26.7M | Put options by funds: $23.2M

13% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 23

10% more capital invested

Capital invested by funds: $1.01B → $1.11B (+$98.2M)

1% more funds holding

Funds holding: 179 → 181 (+2)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

9% less repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 65

1.11% less ownership

Funds ownership: 75.93% → 74.82% (-1.1%)

Holders
181
Holders Change
+2
Holders Change %
+1.12%
% of All Funds
2.84%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
26
Increased
59
Reduced
65
Closed
23
Calls
$26.7M
Puts
$23.2M
Net Calls
+$3.5M
Net Calls Change
+$742K

Top Buyers

1
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$35.5M
2
Ameriprise
Ameriprise
Minnesota
+$24.4M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$23.8M
4
LGM
Logos Global Management
California
+$14.3M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$13.5M

Top Sellers

1
State Street
State Street
Massachusetts
-$22M
2
Citadel Advisors
Citadel Advisors
Florida
-$19.6M
3
Bank of America
Bank of America
North Carolina
-$18.3M
4
BlackRock
BlackRock
New York
-$12.7M
5
PAMS
Pictet Asset Management (Switzerland)
Switzerland
-$12.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$192M -$12.7M -666,983 -7%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$92.6M +$23.8M +1,247,936 +38%
Vanguard Group
3
Vanguard Group
Pennsylvania
$90M +$174K +9,119 +0.2%
State Street
4
State Street
Massachusetts
$88.2M -$22M -1,154,005 -21%
OCA
5
Octagon Capital Advisors
New York
$40M -$3.88M -204,000 -9%
Balyasny Asset Management
6
Balyasny Asset Management
Illinois
$37.9M +$35.5M +1,866,716 New
IFA
7
Invus Financial Advisors
New York
$32.7M – – –
BC
8
Boxer Capital
California
$32.5M +$3.24M +170,000 +12%
Ameriprise
9
Ameriprise
Minnesota
$30M +$24.4M +1,282,961 +658%
PHS
10
PFM Health Sciences
California
$28.5M -$2.95M -154,891 -10%
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
$23.1M -$3.19M -167,597 -13%
AllianceBernstein
12
AllianceBernstein
Tennessee
$21.1M +$428K +22,502 +2%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$20.9M +$966K +50,755 +5%
DCMIC
14
Decheng Capital Management III (Cayman)
Cayman Islands
$17.7M – – –
LGM
15
Logos Global Management
California
$15.2M +$14.3M +750,000 New
Citadel Advisors
16
Citadel Advisors
Florida
$14.9M -$19.6M -1,030,379 -58%
Point72 Asset Management
17
Point72 Asset Management
Connecticut
$14.4M +$13.5M +709,641 New
PAMS
18
Pictet Asset Management (Switzerland)
Switzerland
$12.9M -$12.4M -649,798 -51%
Morgan Stanley
19
Morgan Stanley
New York
$12.6M +$1.23M +64,453 +12%
BNP Paribas Asset Management
20
BNP Paribas Asset Management
France
$12.4M -$3.12M -163,620 -21%
Goldman Sachs
21
Goldman Sachs
New York
$12.1M -$3.93M -206,399 -26%
Northern Trust
22
Northern Trust
Illinois
$10.3M -$451K -23,660 -4%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$9.35M -$346K -18,180 -4%
N
24
Nuveen
North Carolina
$9.3M +$322K +16,902 +4%
American Century Companies
25
American Century Companies
Missouri
$9.02M +$5.71M +299,685 +207%
1
2 3 4 5

RCUS Hedge Fund Activity: Q2 2023 in Review

181 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q2 2023, worth a combined $1.11B — up 9.7% from $1.01B a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new RCUS positions and 23 closed out — a net gain of 3 holders — while 59 added to existing stakes and 65 trimmed.

The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $35.5M. The largest seller was State Street, cutting an estimated $22M.

  • 181 institutional investors held Arcus Biosciences (RCUS) as of Q2 2023, up from 179 in Q1 2023.
  • Funds reported $1.11B of Arcus Biosciences stock for Q2 2023, up 9.7% quarter-over-quarter.
  • 26 funds opened new Arcus Biosciences positions in Q2 2023 and 23 closed out, a net change of +3 holders.
  • The largest Arcus Biosciences buyer in Q2 2023 was Balyasny Asset Management, an estimated $35.5M added.
  • The largest Arcus Biosciences seller in Q2 2023 was State Street, an estimated $22M sold.

Based on aggregated 13F filings for Q2 2023.